420 with CNW — Texas AG Wants Court to Reverse Cannabis Decriminalization in Five Cities

Texas attorney general Ken Paxton is asking the court to overturn cannabis decriminalization policies passed and implemented in five cities and has vowed to overrule the “pro-crime extremists” who championed cannabis reform in the Texas cities. The Republican filed suits against the cities of San Marcos, Austin, Denton, Killeen and Elgin earlier this week to overturn their voter-passed cannabis decriminalization measures.

In the filings, Paxton cited relevant state constitutional and statute provisions and argued that these provisions prevented local governments from approving policies that were in conflict with state law. The AG also issued a press release stating that he would not stand by idly while Texas cities run by “pro-crime” extremists deliberately violated state law and promoted illegal drug use. He added that the municipalities that had enacted cannabis decriminalization laws in the last couple of years took unconstitutional action because cities cannot decide policies to be enforced.

Paxton’s legal action comes as cannabis reform activists with Texas Cannabis Collective and Ground Game Texas work to gather signatures that will allow decriminalization measures to be placed on the November ballot for the cities of Lockhart and Dallas. Lubbock voters will also have the chance to make a decision on a marijuana decriminalization, after legislators allowed a resolution on that issue to be placed on the May ballot.

The decriminalization initiatives passed in Denton, San Marcos, Austin, Killeen, Harker Heights and Elgin prevent law enforcement officers from issuing citations against individuals or arresting them for committing nonviolent or drug-trade-related Class A or B misdemeanor marijuana offenses.

Of the aforementioned cities, Harker Heights is the only city that wasn’t targeted by the AG’s lawsuits, likely because it refused to implement the voter-approved change in policy.

Ground Game Texas’ executive director Julie Oliver stated that the attorney general’s lawsuits were an assault on the authority granted to cities by the constitution, which allowed them to enact their law enforcement policies. Oliver issued a press release noting that a majority of voters in each of the cities cited in the lawsuits were in favor of cannabis decriminalization and the deprioritization of cannabis enforcement.

Oliver explained that voters approved resolutions to minimize racial bias in law enforcement efforts and direct public resources to public safety needs with higher priorities. She added that the AG’s description of promarijuana reform groups in the state as pro-crime organizations was ironic because he is currently being investigated for financial crimes. In her conclusion, Oliver noted that the suits attempted to deflect from the AG’s legal issues and his waning political influence.

The pushback from the attorney general in Texas to local efforts to decriminalize marijuana is likely to be a subject of interest to major marijuana companies such as Canopy Growth Corp. (NASDAQ: CGC) (TSX: WEED). This is because the outcome of those lawsuits could impact the manner in which drug-law-reform efforts progress in other states that have not yet ended prohibition.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Names New Chief Financial Officer

InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, has announced the appointment of Netta Jagpal, CPA, CA, as the newest member of its executive team; Jagpal will serve as the company chief financial officer and corporate secretary, effective Feb. 20, 2024. Jagpal has garnered more than two decades of experience in financial leadership roles, primarily in the biotech industry. Most recently, she was vice president of Financial Reporting & Compliance for D-Wave Systems Inc. (NYSE: QBTS), where she was a key player in the company’s initial public offering process; she also served in a variety of roles, including senior director and finance & corporate controller at Zymeworks Inc. (NYSE: ZYME), a leading Vancouver based clinical stage biopharmaceutical company. She has also worked at Angiotech Pharmaceuticals Inc. and Ernst & Young.

“We are excited to welcome Ms. Jagpal to InMed and are fortunate to have someone of her caliber and experience join our executive leadership team,” said InMed Pharmaceuticals president and CEOEric A. Adams in the press release. “Netta has served in leadership positions with multiple public and private companies and brings a wealth of experience in the biotech industry. Netta’s experience in leading all aspects of the finance and accounting functions makes her an ideal candidate to support both InMed’s core pharmaceutical drug-development business and BayMedica’s commercial enterprise.”

To view the full press release, visit https://cnw.fm/V747F

About InMed Pharmaceuticals Inc.

InMed Pharmaceuticals is a global leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs. Together with its subsidiary, BayMedica, the company has unparalleled cannabinoid manufacturing capabilities to serve a spectrum of consumer markets, including pharmaceutical and health and wellness. InMed is a clinical-stage company developing a pipeline of rare cannabinoid therapeutics and dedicated to delivering new treatment alternatives to patients who may benefit from cannabinoid-based pharmaceutical drugs. For more information, please visit www.InMedPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://cnw.fm/INM

About CannabisNewsWire

CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Senate Democrats Implore Feds to Remove Marijuana from CSA

In a recent letter to the U.S. Drug Enforcement Administration (DEA), 12 Senate Democrat legislators have urged President Joseph Biden’s administration to reconsider federal cannabis restrictions as the agency contemplates cannabis rescheduling. The letter, signed by the Senate Majority Leader and spearheaded by Senators Elizabeth Warren and John Fetterman, highlights the strong argument in favor of taking cannabis out of Schedule I. The senators suggest removing it completely from the CSA in addition to downgrading its classification.

In August 2023, the U.S. Department of Health and Human Services (HSS) recommended moving marijuana from Schedule I to III of the Controlled Substances Act (CSA), a move that triggered an ongoing, months-long review process. Rescheduling or descheduling (removing it from the CSA completely) cannabis would significantly impact the cannabis industry as well as cannabis users, some of whom use it medically.

Schedule I, which formally classifies marijuana as a substance with high abuse potential and no recognized medical uses, puts it in the same category as drugs such as LSD and heroin. Despite this, different marijuana laws have been passed by 40 states as well as Washington, D.C., leaving users and businesses in a confusing legal environment.

Last month, the DEA stated that it maintained the authority to deschedule, schedule or reschedule substances under the CSA based on medical and scientific assessments despite the HHS’s recommendation.

The White House hoped for a rescheduling announcement approximately one year following President Biden’s October 2022 order for the DEA to review the HHS’s recommendation report. Though no statement has been made, it was anticipated that the matter would come up frequently during the elections in November.

In their letter, the senators noted that Biden’s administration needs to first take cannabis out of Schedule I before eventually descheduling it. The government officials highlighted the administration’s unique opportunity to conform to public health and scientific rationales while mitigating the negative effects of existing federal cannabis regulations on small enterprises and individuals.

Meanwhile, Senators Ron Wyden and Cory Booker, who are also signatories to the letter, proposed comprehensive cannabis reform aimed at decriminalizing and abolishing the federal prohibition of marijuana. However, the legislation hasn’t received the required bipartisan support.

Another measure, the SAFE Banking Bill, attempts to make it easier for banks to offer financial services to marijuana enterprises in places where the drug is legal. The measure passed through committee but is still awaiting a senate vote. Schumer has previously emphasized the importance of the bipartisan-backed bill as a top legislative priority.

Cannabis companies such as Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) will be following the developments on Capitol Hill to see whether the legislative front can finally bring reforms beyond what the DEA is expected to announce once its scheduling review is completed.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Officials Say Marijuana Dispute Possibly Linked to Six Fatalities in California

Officials believe the recent California desert killings may have resulted from a dispute over cannabis. After responding to a wellness check request outside the El Mirage community, San Bernardino County Sheriff’s deputies recently discovered the bodies of six individuals at a remote dirt crossroad in the Mojave Desert.

Deputies found the victims in and near two vehicles at a remote intersection after one of the victims called the police and said that he had been shot but didn’t know his location. After tracking the victim’s phone’s location, deputies discovered five bodies in a Chevy Trailblazer and a Dodge Caravan as well as a sixth body some distance away.

Sheriff Shannon Dicus has now revealed that law enforcement officers arrested five suspects in San Bernardino County. According to Sgt. Michael Warrick, the incident “appears to be a dispute over marijuana,” although the scale and reason for the cannabis dispute is still unknown.

California voters legalized recreational cannabis in 2016 via Proposition 64, a ballot initiative that allowed adults 21 years of age and older to possess and consume up to an ounce of recreational cannabis, as well as grow up to six plants at home for personal consumption.

The measure was endorsed by many public figures, including Lt. Governor Gavin Newsom and former Los Angeles Mayor Antonio Villaraigosa; the legislation also was thought to cripple the illegal cannabis trade in California.

However, Sheriff Shannon Dicus says the San Bernardino County desert and other places have been under siege by illegal cannabis growers after the measure’s passage. The sheriff says his office executed 411 illegal grow-related search warrants in 2023 and seized 655,000 cannabis plants, 74,000 pounds of processed cannabis and approximately $370 million. Officers executed 11 of these search warrants in the area immediately adjacent to where the murders took place.

The El Mirage incident is the latest act of violence tied to the cannabis black market in remote areas of California where the cannabis black market is flourishing. Law enforcement is becoming increasingly concerned with the rising death toll and general violence involved in these incidents, especially as illegal cannabis spreads across inland desert communities in Southern California.

The California desert region is now home to multitudes of illegal cannabis farms and has seen a marked increase in violent crime, say residents and law enforcement. Sheriff Shannon Dicus observes that the cannabis black market has become a plague in the San Bernardino County region and notes that cartel activity is certainly involved.

This tragedy highlights the safety risks that the black market poses in the jurisdictions where cannabis is legal. Actors such as Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) are working to avail safe marijuana products to users in lieu of untested products from illicit sources.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

CannabisNewsBreaks – Astrotech Corporation (NASDAQ: ASTC) Introducing Breakthrough Technology, Potential ‘Game Changer’ for the Cannabinoid Industry

Astrotech (NASDAQ: ASTC) is an instrumentation company that is focused on commercializing its proprietary ATi Mass Spectrometer Technology(TM). Its subsidiary, AgLAB Inc., has breakthrough mass spectrometry technology in its AgLAB-1000-D2 mass spectrometer, a ruggedized factory floor analytical instrument designed to quickly and easily analyze complex chemical compounds found in organic plant materials, and the Maximum Value Process(TM) testing method (“AgLAB MVP”). “AgLAB MVP is designed to improve yields and bottom-line profits for hemp (‘CBD’) and cannabis (‘THC’) producers of CBD-THC oils by up to 30%… Using the AgLAB MVP solution, customers are now able to analyze the oils during processing and make near real-time adjustments that can boost the ending-weight yields and potencies,” a recent article reads. “We are proud to introduce the AgLAB MVP, a breakthrough technology that is more accurate and faster than any other testing method. The AgLAB MVP is very fast and is easy to learn with results that more than pay for itself starting on the first day of use. We believe this is a game changer for the cannabinoid industry and processors must use the AgLAB MVP to stay competitive,” said Tom Pickens, CEO and CTO of Astrotech.

To view the full article, visit https://cnw.fm/mu9eF

About Astrotech Corporation

Astrotech is an innovative science and technology company that invents, acquires and commercializes technological innovations while building scalable companies to maximize shareholder value. For more information, please visit www.AstrotechCorp.com.

NOTE TO INVESTORS: The latest news and updates relating to ASTC are available in the company’s newsroom at https://cnw.fm/ASTC

About CannabisNewsWire

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Data Provides Insights on Canadian Cannabis Company Closures in 2023

According to new data given by regulators overseeing the three major Canadian cannabis marketplaces — British Columbia, Ontario and Alberta — an unprecedented number of stores in Canada experienced shutdowns or ownership changes in 2023. The data, sought by MJBizDaily, indicates a retail environment characterized by intense competition in certain places and moderate growth in others.

Alberta saw a shift in dynamics as, for the first time since marijuana was legalized in the province in 2018, more marijuana retail licenses were revoked or not renewed than were issued last year. Forty-eight new marijuana store licenses were issued in the province in 2023, while 62 were not renewed or revoked. This marks a departure from 2022, where 140 new licenses were issued compared to 73 cancellations or nonrenewals.

While the data presents a nuanced picture of store closings, the regulator, AGLC, cautions against drawing straight conclusions about license cancellations and business exits from the industry, noting variables such as relocation.

Alberta is regarded as Canada’s most developed cannabis retail sector, with 749 marijuana providers.

Meanwhile, in Ontario, the country’s largest cannabis market based on sales, new retail cannabis store applications have gradually waned since 2021. More than 1,000 applications for retail stores were submitted in 2021, according to information provided by the regulator, AGCO. More than one-half of applications were lost the next year, to 429 new RSAs, and then another 50% fell to 269 in 2023.

The number of license cancellations has not increased as fast. Only 8 applications were terminated in 2021. In 2022, the number increased to 106, but in 2023, it dropped to 92. According to the data, more retailers are reportedly opening in Ontario than closing.

Only 47 cannabis licenses have been approved in British Columbia (BC) in the last year, which is a drop from the 2022 numbers and around 50% fewer than the 98 permits that were granted in 2021. There were 17 expirations or cancellations in 2023, 6 in 2022 and 12 in 2021, according to data from the LCRB.

Currently, BC has 493 operational cannabis stores. The provincial system does not specifically track store closures; hence, the solicitor general and public safety ministry advise against taking the statistics as an accurate depiction of business closures.

A spokesman for the Public Safety Ministry pointed out that the analysis failed to take license dormancy into consideration, which could result in permanent closures. Dormancy occurs when an establishment ceases operations, requiring license holders to inform the LCRB in 10 days if closure exceeds 90 days.

Stores that fail to disclose closures for less than 90 days and permits that lie idle for up to 24 months also add to the difficulty of keeping track of changes in the business. The number of inactive or unrenewed licenses varies throughout the year due to licensees’ one-year window to reactivate their licenses after they expire.

The continued operation of companies such as Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) is testament to the resilience of the marijuana industry in the country amid the challenges that have stood in the way.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Spotlight PA Legal Victory Opens Door to Cannabis Research

Following a protracted 15-month court battle in 2022, Pennsylvania’s independent newspaper “Spotlight PA,” which specializes in investigative reporting, was able to obtain information about the requirements for the statewide medical cannabis program. The arduous triumph in 2022 opened the door for an extensive inquiry based on those obtained documents, which were released last year.

According to the state’s Department of Health spokesperson, the data has now been shared with other users, including academic researchers throughout the state. The data has also assisted in improving understanding of the state’s medical cannabis program.

Scientists affiliated with Geisinger Healthcare System, including Brian Piper, an assistant professor specializing in neurology at the Geisinger Commonwealth School of Medicine, have been among the beneficiaries of the data. Piper noted how unusual it is for governments to be so open about giving this data, and he described it as a great chance for his research.

Piper and associates leveraged this data to perform a study that examined the relationship between dispensary physical locations vs. the number of adult users with medical cannabis certifications in particular areas. This study also investigated the relationship between dispensary physical locations vs. the proportion of certificates granted for medical problems for which there is insufficient data to conclusively refute or support the efficacy of medical cannabis as a therapeutic substance.

These researchers described their research as the first scientific study within the United States investigating the relationship between qualifying conditions and dispensary locations.

Leading author Annemarie Hirsch, director of the Center for Community Environment & Health and associate professor at Geisinger’s Department of Population Health Sciences, described the research as an attempt to generate hypotheses that might lead to further scientific inquiry.

The study results were presented in the form of a preprint write-up last August, but as of January, the results hadn’t yet gone through the requisite peer-review procedure prior to publication in a scholarly journal. According to Piper, the preprint is a way to quickly share research results with the larger community so that the information might be of use.

In addition, during a review of the literature on anxiety and cannabis last year, the Medical Cannabis Research Center at Drexel University referenced “Spotlight PA”’s data analysis. The review discovered that anxiety issues are the main reason individuals are qualifying for this program.

“Spotlight PA” made the anonymized data on qualifying conditions accessible for public examination online in December to increase openness. The distributed anonymized data respects ethical norms by protecting the anonymity of specific patients and physicians.

As more studies of this nature are conducted, it could lead major marijuana businesses such as Verano Holdings Corp. (CSE: VRNO) (OTCQX: VRNOF) to come up with specially formulated medical marijuana products targeting specific segments of patients in different state-legal markets.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — DEA Settles Lawsuit, Agrees to Rehire Agent Fired for Positive CBD Test

The U.S. Drug Enforcement Administration (DEA) recently rehired an agent that was fired almost five years ago after the agent tested positive for tetrahydrocannabinol during a drug screening. Anthony Armour, the agent in question, was terminated in 2019 by the federal agency.

In 2023, Armour filed a suit against the agency in the Federal Circuit’s Court of Appeals, arguing that the DEA had no grounds to fire him without any evidence that he’d intended to break the law. In his suit, Armour asserted that he was using what he thought to be a hemp product that was federally legal as an alternative to opioids to manage chronic pain.

His attorney, Matt Zorn, also argued that the DEA had no policy on CBD at the time of his client’s termination, which came roughly one year after the 2018 Farm Bill federally legalized hemp and its derivatives. It should be noted that in 2021, the DEA did revise its policy for job applicants, including a section inquiring about prior use of CBD and hemp before federal legalization in its questionnaire.

Last week, the court process ended in Armour’s favor, with the agency agreeing to reinstate him with restored pension eligibility as well as back pay. The Department of Justice, through the lawsuit, acknowledged that during his tenure, the plaintiff was an outstanding agent. The department then highlighted that despite this, his careless conduct in CBD consumption did justify his firing by the DEA.

In an interview, Armour stated that he was excited to return to work at the federal agency and hoped to finish his career by aiding the DEA in its mission to remove dangerous drugs from the streets. He also hopes that marijuana will be legalized, given scientific evidence that supports the drug’s legalization.

In an interview last year, Armour revealed that he was in favor of marijuana legalization.

This settlement agreement comes just as the DEA concludes a review into the scheduling of cannabis under a directive issued by President Joseph Biden in 2022. While the Department of Health and Human Services did recommend that marijuana be moved to Schedule III, the DEA has yet to give its final decision on the matter.

The issue on classification was brought up in Armour’s case, with the primary query being whether marijuana rescheduling would prevent the Drug and Enforcement Administration from enforcing its employment penalty.

The agency still defines an illegal substance as any drug under Schedule I or II of the Controlled Substances Act that cannot be prescribed.

As the scheduling review process nears its end, cannabis companies such as Tilray Brands Inc. (NASDAQ: TLRY) (TSX: TLRY) will be hoping for an outcome that eases many of the hoops that they have been compelled to jump through in order to operate their state-legal businesses within the broader federal regulations, which aren’t so accommodating.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Virginia Senate Committee Advances Cannabis Sales Bill as Deadline Looms

Last week, the Virginia Rehabilitation and Social Services Senate Committee passed a proposal to legalize commercial cannabis sales by a 10 to 5 vote. The bill, SB 448, introduced by Senator Aaron Rouse, aims to initiate the licensing of recreational cannabis businesses starting this July. However, retail licenses would not be accessible until next year.

Subject to voter approval, the measure gives local governments the authority to potentially outlaw commercial marijuana operations.

SB 448 will move on to the Senate’s justice committee next week. Subsequently, it will undergo evaluation in the finance committee, where a crucial deadline of Feb. 5, 2024, looms to keep it in contention. There’s also a crossover date of Feb. 13, 2024, that requires the senate to forward the bill to the house, which is also considering a marijuana sales measure of its own.

During a senate marijuana subcommittee hearing, Rouse’s bill prevailed over an opposing proposal from Senator Adam Ebbin, SB 423. Ebbin’s proposal, which aimed to accelerate adult-use marijuana sales through already-existing dispensaries, was rejected due to worries about possible market dominance by well-established companies.

SB 448 outlines licensing for five business categories, including testing laboratories, cultivators, retailers, manufacturers and transporters. The entities would fall under the regulatory purview of the state’s existing CCA.

Legislators have refrained from debating the bill’s tax components or criminal justice legislation effects thus far, delegating those discussions to the senate’s fiscal and judicial committees.

One amendment suggested during last week’s session is a definition of cultivator size measurement. Cannabis advocates suggest replacing the bill’s maximum of 2,000 plants for the largest cultivators with a cap on canopy square area. However, Rouse objected to this change, claiming that plant counts are simpler to monitor and give small companies greater flexibility.

The subcommittee meeting included a significant amount of debate on social-justice provisions, which emphasized priority licensing for veterans, hemp producers and people from low-income and over-policed communities. Changes that were covered in previous subcommittee sessions included doing away with a clause that prohibited legislators from working in the marijuana industry and forbidding law enforcement from being involved in the business. Additional changes addressed issues such as fairness standards for veterans, testing licensing restrictions to prevent lab shopping and concerns for those impacted by the drug war.

Additionally, the proposal addresses the qualifying standards for marijuana company licenses, prohibiting those with felonies or other convictions involving moral conduct from applying for seven years. There were requests to shorten this exclusion period during the subcommittee meeting.

The legislation arrives against the backdrop of Virginia’s existing legal framework, where recreational cannabis possession, use and personal cultivation are already permitted. Originally a Democrat-controlled legislation from 2021, the framework ran into difficulties due to GOP control over the governor’s office and the house later in the year. The unlicensed market has since expanded as a result of the lack of a newly adopted regulatory framework.

Even if Democrats took back control of both chambers of Congress in November, it is still difficult to pass laws on marijuana sales. There are challenges in reaching a consensus among Democrats and possible resistance from Virginia Governor Glenn Youngkin. Gov. Youngkin has voiced his distaste for cannabis reform and highlighted particular issues, such as labor union regulations for cannabis-related enterprises. Although he first seemed receptive to the notion of commercial sales, more subsequent remarks appear to indicate a change in perspective.

The entire cannabis industry, including sector players such as SNDL Inc. (NASDAQ: SNDL), hope that the launch of adult-use cannabis sales in Virginia happens on schedule so that the residents who aspire to consume this substance can find legal sources to access it.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Republican Research Company Publishes Poll Showing Countrywide Support for Cannabis Legalization

A new poll has found that the majority of voters in America are in favor of cannabis being legalized in all states. The poll conducted by the Tarrance Group involved interviews with about one thousand voters. The interviews were carried out Jan. 3–4, 2024.

The poll determined that 57% of those who responded support nationwide legalization of marijuana. Of this number, 35% admitted to strongly supporting the change in policy. It also found that roughly 55% of GOP voters aged 55 and below supported the legalization of marijuana. In addition, 74% of Democrats aged 55 and below also admitted to supporting the drug’s legalization in all states. Among independent voters, 56% stated that they were in favor of countrywide legalization of marijuana.

It should be noted that various measures have been introduced in Congress that would allow states to make their own decisions concerning marijuana while putting an end to the federal criminalization of the drug.

In an interview, U.S. Cannabis Council’s Josh Glasstetter stated that the survey’s results demonstrated that bipartisan support for the federal legalization of marijuana was growing and a generational shift on marijuana was underway. He then noted that during this year’s election, younger voters who strongly supported legalization would be sought after.

Overall, 67% of voters 18 to 44 years of age say they support a countrywide model to legalize marijuana. This is significantly higher than 57% of those aged 45 to 64 and 47% of those aged 65 and older.

Poll results noted that 68% of President Joseph Biden supporters also favor the reform with 48% of GOP members who support Donald Trump sharing these sentiments. With regard to undecided voters, 50% also support the change in policy.

This poll’s results are similar to those from a separate 2023 survey, which determined that support for ending the federal prohibition of cannabis had hit a new high nationally, with 7 in every 10 Americans supporting the reform. A different survey by Lake Research Partners also found that President Biden stood to make great political gains if cannabis was rescheduled under his administrative directive.

The survey was commissioned by the Coalition for Cannabis Scheduling Reform. The survey comes after the U.S. Department of Health and Human Services completed its scientific review in 2023 and gave its recommendation that marijuana be rescheduled. Despite this recommendation, the matter can only be decided by the DEA.

The drug’s rescheduling may not completely phase out the illicit market, however, Another poll found that nearly one-third of cannabis consumers would return to the illicit market if the drug was rescheduled and then made available solely as an approved prescription drug under the FDA.

The evolving regulatory landscape in the United States is being closely watched by companies such as TerrAscend Corp. (TSX: TSND) (OTCQX: TSNDF) so that these companies can quickly ascertain how any changes made could impact their operations.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com